Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Gelb, Arthur F., M.D. Boehringer Ingelheim Pharmaceuticals Pfizer |
---|---|
Information provided by: | Gelb, Arthur F., M.D. |
ClinicalTrials.gov Identifier: | NCT00570544 |
To evaluate if tiotropium (Spiriva)induced bronchodilation of inspiratory capacity in patients with moderate to severe copd subjected to metronome paced hyperventilation induced dynamic hyperinflation is dependent upon the extent of underlying emphysema as determined by high resolution-thin section CT lung.
Condition | Intervention | Phase |
---|---|---|
COPD Emphysema |
Drug: tiotropium |
Phase IV |
Study Type: | Observational |
Study Design: | Case-Crossover, Retrospective |
Official Title: | Effectiveness of Tiotropium to Maintain Inspiratory Capacity Against Metronome Paced Hyperventilation Induced Dynamic Hyperinflation in COPD Patients With Lung CT Scored Emphysema |
Enrollment: | 29 |
Study Start Date: | August 2004 |
Study Completion Date: | August 2005 |
Groups/Cohorts | Assigned Interventions |
---|---|
1
patients with moderate to severe copd with varying extent of emphysema
|
Drug: tiotropium
18ug capsule daily for 30 days
|
We will analyze post hoc, data that was previously published: Gelb AF et al.Chest 2006;131:690-695. We have shown that tiotropium increases resting inspiratory capacity thereby providing lung volume protection against metronome paced hyperventilation induced dynamic hyperinflation. End point will be to correlate increase in tiotropium induced FEV 1(L) and inspiratory capacity with extent of underlying emphysema as scored by lung CT ( Gelb AF et al:Chest 1996; 109: 353-359)in 29 patients with COPD. We will also correlate the decrease in inspiratory capacity following metronome paced hyperventilation induced dynamic hyperinflation with extent of lung CT scored emphysema.
Ages Eligible for Study: | 40 Years to 85 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
patients with moderate to severe copd from tertiary care pulmonary clinic
Inclusion Criteria
Exclusion Criteria
United States, California | |
Arthur F Gelb Medical Corporation | |
Lakewood, California, United States, 90712 |
Principal Investigator: | Arthur F Gelb, MD | Arthur F Gelb Medical Corporation |
Responsible Party: | Arthur F Gelb Medical Corporation ( Arthur F Gelb MD ) |
Study ID Numbers: | 1000, Boehringer-Ingelheim Pharm., Pfizer |
Study First Received: | December 10, 2007 |
Last Updated: | August 13, 2008 |
ClinicalTrials.gov Identifier: | NCT00570544 |
Health Authority: | United States: Institutional Review Board |
copd emphysema tiotropium lung function dynamic hyperinflation |
Pulmonary Emphysema Emphysema Lung Diseases, Obstructive Respiratory Tract Diseases |
Lung Diseases Benzocaine Tiotropium Pulmonary Disease, Chronic Obstructive |
Parasympatholytics Respiratory System Agents Neurotransmitter Agents Cholinergic Antagonists Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Anti-Asthmatic Agents |
Cholinergic Agents Pharmacologic Actions Pathologic Processes Autonomic Agents Therapeutic Uses Peripheral Nervous System Agents Bronchodilator Agents |